An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a double-masked evaluation of the safety and efficacy of LIPO-102 for the reduction of subcutaneous abdominal adiposity.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Neothetics, Inc

Criteria

Inclusion Criteria:

• Male or non pregnant female

• Good general health

• Sufficient abdominal fat for injections

• Signed informed consent

• BMI greater than or equal to 18 and less than 28 kg/m2

• History of stable weight in past 3 months

Exclusion Criteria:

• Known hypersensitivity to study drugs

• Treatment with an investigational agent within 30 days of first dose